Post by
VentureGecko on Aug 16, 2021 6:21am
BooYAH! - Back to the sewer with you Bashers!
Wholly-owned psychedelics subsidiary Halucenex Life Sciences Inc. secures monumental Controlled Drugs and Substances Dealer’s Licence from Health Canada
• Controlled Drugs and Substances Dealer’s Licence allows Halucenex to possess, sell, transport and conduct R&D on a broad range of psychedelic substances including psilocybin, ketamine, LSD and MDMA amongst others
• Halucenex is now one of few companies globally with a Dealer’s Licence and the ability to work with psilocybin and other psychedelics with Health Canada approval
• Licence significantly increases scope of work in regards to psychedelics and is expected to fast track phase II clinical trial to test psilocybin on treatment-resistant PTSD
• Clinical Trial Application (CTA) lodgement to be expedited – success in trial would unlock a number of future revenue-generating opportunities
• PTSD therapeutics market expected to reach a US$10.5Bn valuation by 2025i
• Established operations in Nova Scotia will provide direct access to a large target market population of veterans – located near some of Canada’s largest army and naval bases
• Halucenex to leverage licence and further establish itself as one of the world’s leading psychedelics companies
• Additional product development and integration opportunities to commence with Mernova Medicinal Inc. as well as other partners
• Further partnership and licensing agreements expected to materialise allowing Halucenex to become a leader in evolutionary treatment routes
• Unlocks access to a large and lucrative opportunity – psychedelic drug market expected to grow to US6.8Bn by 2027ii
Comment by
SamRothstein on Aug 16, 2021 8:23am
Nice! Combined TRIP and CRESO is going to be a monster.